Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Prognostic Value of KRAS Mutations in Colorectal Cancer Patients

Open access

Abstract

Colorectal cancer (CRC) remains a major public health issue. The detection of parameters that affect CRC prognosis is of great significance. KRAS mutations, play a crucial role in tumorigenesis with a strong predictive value. KRAS-mutated stage-IV CRC patients gain no benefit of the anti-EGFR therapy. The KRAS G12C mutation subtype is under investigation for treatment regimens. The present study aimed to detect various RAS mutations in a cohort of 578 RAS-mutated CRC patients; 49% of them had de novo metastatic disease; 60% were male; 71.4% had left-sided tumors; and 94.6% had a good performance status. KRAS mutations were detected in 93.2% of patients, with KRAS G12D being the most common subtype (30.1%). KRAS mutations presented shorter progression-free (PFS) and overall survival (OS), compared with NRAS mutations, although not significantly (PFS: 13.8 vs. 18.5 months; p = 0.552; OS: 53.1 vs. 60.9 months; p = 0.249). KRAS G12D mutations presented better OS rates (p = 0.04). KRAS G12C mutation, even though not significantly, presented worse PFS and OS rates. KRAS exon 3 and 4 mutations presented different PFS and OS rates, although these were not significant. Concluding, KRAS G12D and G12C mutations lead to better and worst prognosis, respectively. Further studies are warranted to validate such findings and their possible therapeutic implication.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers14143320

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 PFS regarding (A)KRAS and NRAS mutations; (B) KRAS G12D, G12C and other KRAS G12 mutations; (C) KRAS exon 2, exon 3 and exon 4 mutations.
Figure 1 PFS regarding (A)KRAS and NRAS mutations; (B) KRAS G12D, G12C and other KRAS G12 mutations; (C) KRAS exon 2, exon 3 and exon 4 mutations.CC BY · PubMed Central
Figure 2 OS regarding (A) KRAS- and NRAS-mutated patients; (B) KRAS G12D and other KRAS G12 mutations; (C) KRAS G12D, G12C and other G12 mutations; (D) KRAS exon 2, exon 3 and exon 4 mutations.
Figure 2 OS regarding (A) KRAS- and NRAS-mutated patients; (B) KRAS G12D and other KRAS G12 mutations; (C) KRAS G12D, G12C and other G12 mutations; (D) KRAS exon 2, exon 3 and exon 4 mutations.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 63

Metadata

Authors
Koulouridi, A., Karagianni, M., Messaritakis, I., Sfakianaki, M., Voutsina, A., Trypaki, M., Bachlitzanaki, M., Koustas, E., Karamouzis, M. V., Ntavatzikos, A., Koumarianou, A., Androulakis, N., Mavroudis, D., Tzardi, M., & Souglakos, J.
Affiliations
  • University of Crete (GR)
  • The General Hospital of Heraklion "Venizeleio-Pananio" (GR)
  • National and Kapodistrian University of Athens (GR)
  • Laboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece
Corresponding author
  • Messaritakis, Ippokratis
  • Souglakos, John
Venue
Cancers
Publisher
MDPI AG
Published
2022-07-07
Volume
14
Issue
14
Pages
3320
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4284894231
Cited by
63
References
32
Citations by year
2026: 9 · 2025: 18 · 2024: 21 · 2023: 14 · 2022: 1
FWCI
5.65
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Gastrointestinal Research Study Group
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
KRAS mutation, colorectal cancer, prognostic value, KRAS G12D, KRAS G12C, NRAS mutation, progression-free survival, overall survival, metastatic colorectal cancer, anti-EGFR therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic Value of KRAS Mutations in Colorectal Cancer Patients. https://app.cochat.ai/papers/10.3390/cancers14143320
The paper
Koulouridi, A., Karagianni, M., Messaritakis, I., Sfakianaki, M., Voutsina, A., Trypaki, M., Bachlitzanaki, M., Koustas, E., Karamouzis, M. V., Ntavatzikos, A., Koumarianou, A., Androulakis, N., Mavroudis, D., Tzardi, M., & Souglakos, J. (2022). Prognostic Value of KRAS Mutations in Colorectal Cancer Patients. Cancers. https://doi.org/10.3390/cancers14143320

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.